Huron Consulting
HURN
156.61
-0.65
-0.41%
Huron Consulting
US · HURN
#2616 by market cap
Listed 1970
156.61
-0.65
-0.41%
Live - 5344 symbols - heartbeat 520s ago
· 2026-10-07 19:54
After-hours
156.61
0.00%
- Market cap
- 2.49B
- P/E (TTM)i
- 23.59
- P/Bi
- 6.48
- EPSi
- 5.84
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on HURN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.65, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.65% YoY
Margins
- Gross margin
- 31.81%
- Operating margin
- 11.05%
- Net margin
- 6.18%
Key ratios & quality
- Enterprise valuei
- 2.99B
- PEG ratioi
- 2.03
- Altman Z-Scorei
- 3.65
PEG uses trailing P/E against the 3-year net income growth rate (11.61%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 878.00M | 965.47M | 871.01M | 926.96M | 1.16B | 1.40B | 1.52B | 1.70B |
| Gross profit | 273.54M | 301.18M | 251.67M | 268.81M | 346.41M | 419.29M | 476.01M | 540.41M |
| Selling & admin expenses | 180.98M | 203.07M | 170.54M | 178.08M | 209.57M | 257.93M | 286.66M | 318.02M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 53.73M | 64.37M | 51.49M | 65.24M | 109.67M | 136.90M | 178.73M | 187.71M |
| Pretax profit | 25.22M | 52.49M | -33.87M | 80.04M | 108.58M | 83.90M | 154.02M | 135.08M |
| Tax | 11.28M | 10.51M | -10.16M | 17.05M | 33.03M | 21.42M | 37.39M | 30.04M |
| Net profit | 13.65M | 41.74M | -23.84M | 62.99M | 75.55M | 62.48M | 116.63M | 105.04M |
| Basic EPS | 1 | 2 | -1 | 3 | 4 | 3 | 7 | 6 |
| Diluted EPS | 0.62 | 1.85 | -1.09 | 2.89 | 3.64 | 3.19 | 6.27 | 5.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 404.14M | 411.76M | 441.28M | 441.96M | 451.77M | 475.04M |
| Gross profit | 117.65M | 133.48M | 143.56M | 145.73M | 135.52M | 154.45M |
| Selling & admin expenses | 76.63M | 80.22M | 81.30M | 79.87M | 84.71M | 89.79M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 34.07M | 46.21M | 53.52M | 53.90M | 37.25M | 50.66M |
| Pretax profit | 21.45M | 27.71M | 42.65M | 43.27M | 27.07M | 42.91M |
| Tax | -3.08M | 8.28M | 12.23M | 12.62M | 3.82M | 11.67M |
| Net profit | 24.54M | 19.43M | 30.42M | 30.65M | 23.25M | 31.23M |
| Basic EPS | 1 | 1 | 2 | 2 | 1 | 2 |
| Diluted EPS | 1.33 | 1.09 | 1.71 | 1.72 | 1.34 | 1.91 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 232.93M | 224.74M | 230.51M | 257.68M | 328.48M | 400.46M | 409.12M | 448.58M |
| Cash & ST investments | 33.11M | 11.60M | 67.18M | 20.78M | 11.83M | 12.15M | 21.91M | 24.51M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.05B | 1.10B | 1.05B | 1.12B | 1.20B | 1.26B | 1.34B | 1.53B |
| Total current liabilities | 418.31M | 204.54M | 186.87M | 205.18M | 245.68M | 302.58M | 338.82M | 383.43M |
| Short-term debt | 243.13M | 8.00M | 9.27M | 10.70M | 10.53M | 11.03M | 26.07M | 34.30M |
| Long-term debt | 53.85M | 208.32M | 202.78M | 232.22M | 290.00M | 324.00M | 342.86M | 489.67M |
| Total liabilities | 508,908,000.00 | 518,806,000.00 | 499,033,000.00 | 547,449,000.00 | 647,000,000.00 | 729,250,000.00 | 782,290,000.00 | 998,054,000.00 |
| Total equity | 540.62M | 585.47M | 551.94M | 571.90M | 552.04M | 532.89M | 561.33M | 528.63M |
| Retained earnings | 196.11M | 237.85M | 214.01M | 277.00M | 352.55M | 415.03M | 531.65M | 636.69M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 439.97M | 490.44M | 475.05M | 448.58M | 514.74M | 529.78M |
| Cash & ST investments | 23.38M | 61.01M | 23.89M | 24.51M | 26.46M | 31.23M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.36B | 1.48B | 1.54B | 1.53B | 1.59B | 1.64B |
| Total current liabilities | 211.49M | 246.89M | 330.05M | 383.43M | 232.17M | 309.93M |
| Short-term debt | 26.25M | 26.00M | 34.13M | 34.30M | 31.22M | 29.80M |
| Long-term debt | 561.51M | 643.17M | 589.59M | 489.67M | 834.74M | 812.81M |
| Total liabilities | 869,282,000.00 | 1,005,817,000.00 | 1,044,404,000.00 | 998,054,000.00 | 1,191,685,000.00 | 1,260,000,000.00 |
| Total equity | 494.28M | 475.00M | 499.78M | 528.63M | 397.44M | 384.76M |
| Retained earnings | 556.19M | 575.62M | 606.04M | 636.69M | 608.28M | 599.38M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 101.66M | 132.22M | 136.74M | 17.99M | 85.40M | 135.26M | 201.32M | 193.39M |
| Depreciation & amortization | 39.31M | 34.41M | 30.22M | 25.98M | 27.36M | 24.94M | 25.30M | 32.43M |
| Free cash flow | 86.65M | 108.67M | 120.34M | 2.23M | 61.10M | 100.08M | 168.74M | 162.31M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -3.19M | -18.37M | -35.04M | -74.72M | -128.19M | -133.29M | -145.09M | -200.29M |
| Ending cash balance | 33.11M | 11.60M | 67.18M | 20.78M | 11.83M | 12.15M | 21.91M | 24.51M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -106.83M | 80.05M | 93.77M | 126.41M | -162.17M | 120.47M |
| Depreciation & amortization | 6.95M | 7.12M | 9.40M | 8.97M | 9.72M | 10.15M |
| Free cash flow | -115.36M | 73.77M | 85.31M | 118.59M | -174.03M | 111.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -97.49M | -69.39M | -19.20M | -14.22M | -173.66M | -53.80M |
| Ending cash balance | 23.38M | 61.01M | 23.89M | 24.51M | 26.46M | 31.23M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 2.61 | 7.41 | -4.19 | 11.21 | 13.44 | 11.52 | 21.32 | 19.27 |
| ROA %i | 1.31 | 3.88 | -2.21 | 5.79 | 6.52 | 5.08 | 8.95 | 7.32 |
| ROIC %i | 1.42 | 4.89 | -2.81 | 7.43 | 8.55 | 6.92 | 12.50 | 10.31 |
| 5-year avg ROE %i | 0.45 | -0.86 | -3.59 | -2.50 | 6.10 | 7.88 | 10.66 | 15.35 |
| EBIT margin %i | 6.35 | 6.67 | 5.89 | 7.06 | 9.46 | 9.79 | 11.74 | 11.05 |
| FCF / sales %i | 9.87 | 11.26 | 13.82 | 0.24 | 5.27 | 7.15 | 11.09 | 9.55 |
| Current ratioi | 0.56 | 1.10 | 1.23 | 1.26 | 1.34 | 1.32 | 1.21 | 1.17 |
| Quick ratioi | 0.52 | 1.03 | 1.14 | 1.18 | 1.23 | 1.23 | 1.12 | 1.08 |
| Debt / assetsi | 28.30 | 25.86 | 26.06 | 26.55 | 28.86 | 29.62 | 29.67 | 35.92 |
| LT debt / equityi | 9.96 | 47.41 | 47.94 | 50.10 | 60.78 | 68.09 | 66.37 | 97.24 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 4.52 | 6.56 | 2.55 | 1.83 | 6.28 | 17.10 | 17.97 | 13.60 |
| Net income CAGR (3Y) %i | -38.63 | 3.53 | -- | 66.50 | 21.87 | -- | 22.80 | 11.61 |
| FCF CAGR (3Y) %i | -16.42 | -1.65 | 17.58 | -70.49 | -17.46 | -5.96 | 323.15 | 38.49 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 24.88 | 21.55 | 21.20 | 19.27 | 23.27 | 26.88 |
| ROA %i | 9.09 | 7.49 | 7.54 | 7.32 | 7.03 | 7.39 |
| ROIC %i | 11.07 | 9.44 | 10.03 | 10.31 | 8.67 | 9.56 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 12.19 | 11.00 | 11.06 | 11.05 | 10.93 | 10.79 |
| FCF / sales %i | 12.35 | 10.57 | 10.63 | 9.55 | 5.93 | 7.80 |
| Current ratioi | 2.08 | 1.99 | 1.44 | 1.17 | 2.22 | 1.71 |
| Quick ratioi | 1.95 | 1.87 | 1.33 | 1.08 | 2.07 | 1.58 |
| Debt / assetsi | 45.10 | 46.86 | 42.15 | 35.92 | 55.84 | 52.56 |
| LT debt / equityi | 119.11 | 140.61 | 123.41 | 97.24 | 215.43 | 216.95 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Healthcare is the largest reported line at 49.86% of revenue, across 3 reported segments.
- Education follows at 29.93%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Healthcare49.86%
Education29.93%
Commercial20.21%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.